Blair William & CO Synthetic Biologics, Inc. Transaction History

Blair William & CO

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$1.9 - $2.9 $86,567 - $132,129	45,562 Added 17.69%	303,152 $65,000
Q1 2022 May 13, 2022	BUY	$2.3 - $4.3 $95,452 - $178,454	41,501 Added 19.21%	257,590 $73,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.5 $33,604 - $56,007	12,446 Added 6.11%	216,089 $59,000
Q3 2021 Nov 12, 2021	BUY	$4.3 - $5.8 $139,070 - $187,583	32,342 Added 18.88%	203,643 $94,000
Q2 2021 Aug 12, 2021	BUY	$4.6 - $7.2 $462,336 - $723,657	100,508 Added 141.97%	171,301 $103,000
Q1 2021 May 13, 2021	BUY	$5.0 - $11.7 $81,280 - $190,195	16,256 Added 29.81%	70,793 $48,000
Q4 2020 Feb 09, 2021	BUY	$2.9 - $4.6 $4,857 - $7,704	1,675 Added 3.17%	54,537 $21,000
Q3 2020 Nov 06, 2020	SELL	$4.5 - $7.1 $36,594 - $57,737	-8,132 Reduced 13.33%	52,862 $25,000
Q2 2020 Aug 12, 2020	BUY	$2.8 - $5.7 $17,869 - $36,377	6,382 Added 11.69%	60,994 $31,000
Q1 2020 May 11, 2020	BUY	$2.7 - $6.1 $9,039 - $20,422	3,348 Added 6.53%	54,612 $18,000
Q4 2019 Feb 13, 2020	SELL	$3.9 - $5.3 $6,594 - $8,962	-1,691 Reduced 3.19%	51,264 $26,000
Q3 2019 Nov 12, 2019	SELL	$3.9 - $5.9 $4,262 - $6,448	-1,093 Reduced 2.02%	52,955 $24,000
Q2 2019 Aug 13, 2019	SELL	$4.9 - $6.6 $12,328 - $16,605	-2,516 Reduced 4.45%	54,048 $30,000
Q1 2019 May 14, 2019	BUY	$5.9 - $8.1 $70,859 - $97,281	12,010 Added 26.96%	56,564 $38,000
Q4 2018 Feb 14, 2019	BUY	$5.2 - $26.8 $231,680 - $1.19 Million	44,554 New	44,554 $25,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.